 |
26 Companies | 20 Products |
|
|
20 Products | |
267 Diseases | |
19 Trials |  |
2308 News |  |
| «12345678910111213...2122» |
- | Journal: Dual Modes of Gene Regulation by CDK12. (Pubmed Central) - Oct 3, 2025
Indeed, in HER2+ breast cancer, a malignancy where CDK12 is co-amplified with HER2 and its expression correlates with disease status, CDK12 inhibition markedly elevates MYC expression to induce lethality. The dual effects of CDK12 inhibition elucidated herein clarify its role in transcriptional control and have significant translational implications.
- | enitociclib (VIP152) / Vincerx, zemirciclib (AZD4573) / AstraZeneca
Journal: YX0798 Is a Highly Potent, Selective, and Orally Effective CDK9 Inhibitor for Treating Aggressive Lymphoma. (Pubmed Central) - Sep 30, 2025
Furthermore, YX0798 has the potential to be used in combination therapy with clinical agents to improve treatment efficacy. Together, these data demonstrate that YX0798 has oral bioavailability, exquisite selectivity, and anti-tumor potency that results from driving transcription reprogramming towards tumor cell killing.
- | Preclinical, Journal: Computationally Motivated Discovery of Biogenic Compounds with Potent CDK9 Inhibition and In Vitro Effects against Glioblastoma. (Pubmed Central) - Sep 25, 2025
The compounds had good predicted oral bioavailability and four of the six inhibitors potential for blood-brain barrier permeability. Given their structural novelty, the identified CDK9 inhibitor scaffolds can be further explored for their potential against CNS conditions, including 1 and 7 against GBM.
- | Venclexta (venetoclax) / Roche, AbbVie, enitociclib (VIP152) / Vincerx
Journal: Targeting CDK9 inhibits the growth of KMT2A-rearranged infant leukemia and demonstrates synergy with menin inhibition. (Pubmed Central) - Sep 22, 2025
Enitociclib also potentiates the cytotoxicity of venetoclax in relatively venetoclax-resistant KMT2A-r leukemic cells. Overall, enitociclib has shown measurable in vitro antitumor activity in KMT2A-r infant leukemia and is a rational therapeutic option to explore in future clinical trials.
- | Journal: Translational Research on the Oral Delivery of the Cytotoxic PROTAC Molecule via Tumor-Targeting Prodrug Strategy for Triple-Negative Breast Cancer Treatment. (Pubmed Central) - Sep 22, 2025
To address this challenge, we identified an oral bioavailable and tumor-targeting prodrug that substantially reduces systemic exposure of the PROTAC compound while enabling significant tumor-specific enrichment. This prodrug effectively and safely inhibits TNBC cell proliferation in multiple cell line-derived xenografts (CDX) and patient-derived xenograft (PDX) models, positioning it as a promising candidate for targeted TNBC therapy.
- | atuveciclib (BAY 1143572) / Bayer
Journal: Design, Synthesis, and Biological Evaluation of Sulfonamide Derivatives as Potent CDK9 Inhibitors. (Pubmed Central) - Sep 17, 2025
To obtain CDK9 inhibitors with high activity and safety, we designed and synthesized a series of sulfonamide derivatives as CDK9 inhibitors based on BAY1143572, the first selective CDK9 inhibitor to enter clinical trials...Further studies showed that L18 possessed moderate metabolic properties and exhibited an in vivo safety profile superior to that of the positive control. This study provides a potential lead compound for the development of CDK9 inhibitors for cancer therapy.
- | Lunsumio (mosunetuzumab-axgb) / Roche, Rituxan (rituximab) / Roche, Epkinly (epcoritamab-bysp) / Genmab, AbbVie
Review, Journal, IO biomarker: Richter Transformation in Chronic Lymphocytic Leukemia: Current Treatment Challenges and Evolving Therapies. (Pubmed Central) - Sep 17, 2025
This study provides a potential lead compound for the development of CDK9 inhibitors for cancer therapy. Traditional chemoimmunotherapy (e.g., R-CHOP) yields complete response rates around 20-30% and median overall survival of 6-12 months; intensified regimens (R-EPOCH, hyper-CVAD) offer only modest gains...Bispecific antibodies (e.g., CD3
- | Journal: Inhibition of CDK9 enhances AML cell death induced by combined venetoclax and azacitidine. (Pubmed Central) - Sep 16, 2025
The roles of MCL-1 and c-MYC in the three-drug combination were confirmed by knockdown. This study demonstrates that AZD4573 enhances the activity of VEN?+?AZA against AraC-resistant AML by downregulating c-MYC and MCL-1 and to a lesser extent cellular respiration.
- | bleomycin / Generic mfg., alvocidib (DSP-2033) / Sumitomo Pharma, nintedanib / Generic mfg.
Journal: Repurposing flavopiridol as an inhaled therapeutic for pulmonary fibrosis. (Pubmed Central) - Sep 16, 2025
Further, we developed an inhalable formulation of flavopiridol and demonstrated its efficacy in mitigating fibrosis through local lung delivery, which minimized systemic drug exposure and potential adverse effects. These findings establish CDK9 as a critical regulator of lung fibrosis and provide compelling evidence for developing CDK9 inhibitors as novel therapeutic agents for IPF.
- | enitociclib (VIP152) / Vincerx
Journal: Phenotypic screening converges on CDK9 inhibition as a therapeutic strategy in translocation renal cell carcinoma. (Pubmed Central) - Sep 5, 2025
These effects were recapitulated by the CDK9-selective inhibitor enitociclib, which downregulated TFE3 targets and suppressed tRCC cell growth. Our findings nominate CDK9 inhibition as a therapeutic strategy in tRCC and demonstrate the utility of mechanism-informed phenotypic screening for challenging targets.
- | enitociclib (VIP152) / Vincerx
Journal: Hepatitis B surface antigen is upregulated by HIV Tat in an HIV-hepatitis B virus co-infection model system. (Pubmed Central) - Sep 4, 2025
This could be rescued by CDK9 inhibition with BAY-1251152...Our findings have implications for interventions aiming to cure HIV through latency reversal, as these interventions can specifically increase the Tat protein. Future exploratory treatment strategies, such as Tat inhibitors, could play a role in the management of people with HIV and HBV at high risk of liver disease.
- | alvocidib (DSP-2033) / Sumitomo Pharma
Journal: Total Synthesis of Rohitukine and Dysoline and Their Anticancer Analogues Flavopiridol and IIIM-290. (Pubmed Central) - Sep 4, 2025
The CDK9/T1 inhibition study indicates that a piperidine ring at the C8 position of the chromone nucleus is crucial, as C6-regioisomers show significantly reduced or no inhibition. The developed method for producing clinically important piperidine alkaloids is straightforward, is scalable, and involves only a few chromatographic purification steps.
- HDAC and CDK Inhibitor Combinations Synergize in Limiting Myeloma () - Aug 29, 2025 - Abstract #IMS2025IMS_811;
The developed method for producing clinically important piperidine alkaloids is straightforward, is scalable, and involves only a few chromatographic purification steps. Further investigation into a combined genetic signature will aid in discovering mechanisms of drug synergy and provide biomarkers for a combined response that may translate to the clinic.
- | Keytruda (pembrolizumab) / Merck (MSD)
Journal, PD(L)-1 Biomarker: CREPT promotes LUAD progression by enhancing the CDK9 and RNAPII assembly to promote ERK-driven gene transcription. (Pubmed Central) - Aug 27, 2025
Furthermore, in a humanized mouse model, AAV-mediated CREPT silencing inhibited tumor progression and showed synergistic potential with pembrolizumab. Our findings highlight CREPT as a pivotal regulator of LUAD progression and suggest it could be a potential therapeutic target for patients with EGFR or KRAS mutations insensitive or resistant to targeted therapies.
- | Journal, BRCA Biomarker, PARP Biomarker: SMARCA4 loss increases RNA Polymerase II pausing and elevates R-loops to inhibit BRCA1-mediated repair in ovarian cancer. (Pubmed Central) - Aug 25, 2025
Co-targeting PARP/CDK9 also elicited synergistic effects against other undifferentiated ovarian cancer cells with SMARCA4 loss. These findings link SMARCA4 loss to perturbed Pol II elongation and compromised DNA repair by BRCA1, providing a therapeutic opportunity to target SCCOHT and other SWI/SNF-deficient ovarian cancers.
- || Review, Journal: Advances in KEAP1-based PROTACs as emerging therapeutic modalities: Structural basis and progress. (Pubmed Central) - Aug 24, 2025
However, current challenges in KEAP1-based targeted protein degradation warrant further investigation to fully realize its therapeutic potential. Future research should focus on optimizing KEAP1 ligand properties and exploring novel protein targets amenable to degradation via KEAP1 recruitment to further advance this innovative therapeutic modality.
- | enitociclib (VIP152) / Vincerx, zemirciclib (AZD4573) / AstraZeneca
Journal: Cyclin-dependent kinase 9 inhibitors as oncogene signaling modulators in combination with targeted therapy for the treatment of colorectal cancer. (Pubmed Central) - Aug 20, 2025
MAPK signaling is particularly suppressed by CDK9 inhibitors. Combining CDK9 inhibitors and targeted therapy against MAPK signaling pathway may be a viable strategy worthy of further investigation preclinically and clinically.
- | Venclexta (venetoclax) / Roche, AbbVie, voruciclib (ME-522) / MEI
Journal: The oral CDK9 inhibitor voruciclib combined with venetoclax for patients with relapsed/refractory acute myeloid leukemia. (Pubmed Central) - Aug 14, 2025
P1
Overall, the combination of voruciclib with venetoclax was tolerable in patients with relapsed/refractory AML, had antileukemic activity, and showed on-target effects in heavily pretreated patients with disease progression after venetoclax. This trial was registered at www.ClinicalTrials.gov as #NCT03547115.
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal: Targeting CDK9 With Harmine Induces Homologous Recombination Deficiency and Synergizes With PARP Inhibitors in Ovarian Cancer. (Pubmed Central) - Aug 11, 2025
Moreover, harmine synergized with PARP inhibitor olaparib in BRCA1/2 wild-type ovarian cancer. Harmine inhibits HR repair by interfering with CDK9-mediated transcription elongation for HR-related genes, thus enhancing the potency of olaparib, providing a promising therapeutic strategy to improve the prognosis of HR-proficient ovarian cancer patients.
- | Journal: Single-molecule live imaging of subunit interactions and exchange within cellular regulatory complexes. (Pubmed Central) - Aug 9, 2025
Finally, PAPA detected the release of P-TEFb from 7SK by the HIV transcriptional activator Tat. Our results illuminate aspects of P-TEFb regulation that were previously inaccessible in live cells and open a route to probe subunit interactions and exchange within endogenous regulatory complexes.
- || European regulatory, Review, Journal: Paediatric strategy forum for medicinal product development of cyclin-dependent kinase inhibitors in children and adolescents ACCELERATE in collaboration with the European Medicines Agency With participation of the Food and Drug Administration. (Pubmed Central) - Aug 9, 2025
Based on limited single agent activity in preclinical models, trials of new inhibitors should avoid unnecessary exposure of patients to monotherapy and rapidly progress to combination strategies, while retaining designs that allow early evaluation of activity. A framework to support integrated development strategies of new products across sponsors would be very beneficial.
- || Review, Journal, PARP Biomarker, PD(L)-1 Biomarker, IO biomarker: An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 - present): part 2 - patent published. (Pubmed Central) - Aug 1, 2025
The HDAC inhibitor(s) in combination with other therapeutically relevant inhibitor(s) such as MAPK, GSK3, PI3K/mTOR, PARP, CDK9, HSP90, BTK, BRD4, JAK, VEGF, ALK, PD-1, or PDE inhibitor etc. showed synergistic anti-cancer activity. These combinations not only overcame drug resistance but also acted against relapsed/refractory cancers.
- | Journal: Comprehensive analysis of cholesterol metabolism-related genes in prostate cancer: integrated analysis of single-cell and bulk RNA sequencing. (Pubmed Central) - Jul 30, 2025
The CMG-based prognostic model effectively predicts prognosis in PRAD patients and is linked to distinct biological pathways, immune landscapes, and drug sensitivities. This signature has the robust potential to guide personalized therapy and improve prognosis in PRAD.
- || Review, Journal, IO biomarker: Chronic Lymphocytic Leukemia: Novel Therapeutic Targets Under Investigation. (Pubmed Central) - Jul 29, 2025
This review provides an in-depth overview of the promising novel treatment approaches under investigation in CLL, focusing on advanced cellular therapies (CAR T-cell therapy), T-cell engagers, new monoclonal antibodies, and various next-generation small molecule inhibitors including BTK degraders, PI3K inhibitors, MALT1 inhibitors, c-MYC inhibitors, CDK9 inhibitors, and agents targeting angiogenesis and DNA damage repair. In this review, we will discuss the novel therapeutic targets and agents as well as ongoing trials, emphasizing the potential of these treatments to overcome resistance and meet the unmet needs of patients, particularly those with double-refractory CLL.
- Venclexta (venetoclax) / Roche, AbbVie
CDK9 inhibition enhances venetoclax activity and prolongs survival in a T-PLL patient-derived xenograft model (Hall 25) - Jul 24, 2025 - Abstract #ESMO2025ESMO_2788;
Our T-PLL PDX model can be used to evaluate the effect of new drugs for T-PLL in a preclinical setting. Legal entity responsible for the study The authors.
- | Journal: Dual CDK6 and CDK9 inhibitors as anti-psoriasis agents: Design, synthesis, and anti-inflammatory activity. (Pubmed Central) - Jul 14, 2025
Furthermore, it inhibited the activation of STAT3 pathway and decreased the mRNA levels of inflammatory factors in IFN-?/TNF-?-induced HaCaT cells. These findings indicate dual CDK6 and CDK9 inhibitors may emerge as potential therapeutic agents for psoriasis.
- | Verzenio (abemaciclib) / Eli Lilly
Journal: Abemaciclib induces G1 arrest and lysosomal dysfunction in canine melanoma cells: synergistic effects with fenbendazole. (Pubmed Central) - Jul 11, 2025
These findings demonstrate that abemaciclib exerts potent antitumor effects in canine melanoma by inducing cell cycle arrest and disrupting lysosomal function. Its synergistic interaction with fenbendazole suggests a potential combinatorial therapeutic approach for canine melanoma.
- | Journal: Discovery and optimization of novel tetrahydrothiazolopyridine-based pyrimidines as highly potent cyclin-dependent kinase 9 (CDK9) inhibitors. (Pubmed Central) - Jul 10, 2025
Its synergistic interaction with fenbendazole suggests a potential combinatorial therapeutic approach for canine melanoma. Research on the mechanism reveals that 8e could concentration-dependently cause the G2/M phase arrest and induce cell apoptosis in HCT116
- | Journal: BRD4 acts as a transcriptional repressor of RhoB to inhibit terminal erythropoiesis. (Pubmed Central) - Jul 2, 2025
Besides, we clarify RhoB's activity and function during terminal erythropoiesis. BRD4 inhibition might be a simple method to promote in vitro blood cell production, and a candidate therapeutic target for diseases leading to dyserythropoiesis such as myelodysplastic syndromes.
- | Journal: Mapping the nuclear landscape with multiplexed super-resolution fluorescence microscopy. (Pubmed Central) - Jul 2, 2025
Perturbing histone acetylation or transcription disrupted nanoscale organization but had less effect at the microscale. We envision that our imaging and analysis pipeline will be useful to reveal the organizational principles not only of the cell nucleus but also other cellular compartments.
- OBP-004 / OncoBone Therapeutics
OBP-004, a highly potent selective small-molecule dual inhibitor of CDK9/13 reduces bone metastatic growth, cancer-induced bone loss and bone pain of triple-negative breast cancer and castration-resistant prostate cancer in preclinical models (Discovery Hall) - Jul 1, 2025 - Abstract #ASBMR2025ASBMR_841;
We conclude that OBP-004, a highly potent selective dual inhibitor of CDK9/CDK13, is a promising preclinical drug candidate for the treatment of bone metastatic TNBC and CRPC. The observed decreased bone pain indicates potential for increasing the quality of life of bone metastatic patients.
- Characterization of apoptosis inducing natural compounds for the treatment of therapy resistant tumors - with focus on CDK inhibitors (Poster and Exhibition Hall; Poster Board No EACR25-3025) - Jun 29, 2025 - Abstract #EACR2025EACR_1857;
The observed decreased bone pain indicates potential for increasing the quality of life of bone metastatic patients. These findings highlight the therapeutic potential of CDK9 inhibition as a targeted strategy to effectively induce apoptosis in leukemia cells over transcriptional inhibition.
- SNS-032 / Viracta Therap
Design and synthesis of CDK9/EZH2 dual-target inhibitors to achieve synergistic antitumor effects (Poster and Exhibition Hall; Poster Board No EACR25-0660) - Jun 29, 2025 - Abstract #EACR2025EACR_887;
Notably, compound D16 induced greater DNA damage and exhibited stronger inhibitory effects on DLBCL proliferation compared to the single-target inhibitor SNS-032 or C24. All these findings highlight the potential of dual CDK9/EZH2 inhibitors as a novel approach for cancer therapy.
- temozolomide / Generic mfg.
Dual targeting BRD4-CDK9 transcriptional complex as a potent therapeutic strategy in glioblastoma (Poster and Exhibition Hall; Poster Board No EACR25-2108) - Jun 29, 2025 - Abstract #EACR2025EACR_848;
Available therapies, such as radiotherapy and chemotherapy with temozolomide (TMZ), offer a median survival of only 15 months after diagnosis... Combined inhibition of BRD4 and CDK9 shows promise as a potential therapeutic strategy for the treatment of GBM.
- | enitociclib (VIP152) / Vincerx
Preclinical, Journal: Enitociclib, a selective CDK9 inhibitor: in (Pubmed Central) - Jun 23, 2025
Additionally, enitociclib demonstrated synergistic effects with several anti-MM agents, including bortezomib, lenalidomide, pomalidomide, and venetoclax. These results suggest that enitociclib may represent a promising therapeutic option for the treatment of MM, either as a single agent or in combination with other anti-MM agents.
- || Review, Journal: Research Progress of PROTAC-Degraded CDKs in the Treatment of Breast Cancer. (Pubmed Central) - Jun 19, 2025
After binding to POI, PROTAC can recruit E3 to ubiquitinate POI via ubiquitin-proteasome mediated degradation. In this review, we summarize relevant research results and review that PROTAC can effectively inhibit the proliferation of breast cancer cells by inducing ubiquitination of CDK1, CDK4/6, CDK9, CDK12/13 and their subsequent degradation by proteasomes, which is expected to be a novel approach for the treatment of breast cancer.
- || PK/PD data, Preclinical, Journal: Discovery and Administration Optimization of Novel Selective CDK9 Inhibitor, 1-7a-B1, for Improved Pharmacokinetics and Antitumor Efficacy In Vivo. (Pubmed Central) - Jun 12, 2025
This study provides a solution for an oral administration strategy for molecules with strong first-pass elimination. Currently, this emulsion system is being researched further for CRC treatment.
- | xirestomig (ATG-101) / Antengene
Journal: First ATG101-recruiting small molecule degrader for selective CDK9 degradation via autophagy-lysosome pathway. (Pubmed Central) - Jun 9, 2025
Mechanism research revealed that AZ-9 recruits ATG101 to initiate the autophagy-lysosome pathway, and forms autophagosomes through the recruitment of LC3, which then fuses with lysosomes to degrade CDK9 and the partner protein Cyclin T1. These dates validated the existence of non-proteasomal degradation pathway of hydrophobic driven protein degradation strategy for the first time, which might provide research ideas for chemical induction intervention on other types of pathogenic proteins.
- | xirestomig (ATG-101) / Antengene
Journal: Innovative discovery and mechanistic validation of HyT-PD ligands for selective CDK9-targeted protein degradation. (Pubmed Central) - Jun 9, 2025
These dates validated the existence of non-proteasomal degradation pathway of hydrophobic driven protein degradation strategy for the first time, which might provide research ideas for chemical induction intervention on other types of pathogenic proteins. No abstract available
- | mocetinostat (MGCD0103) / Otsuka, BMS, TT001 / Ting Therap
Journal: Design, synthesis, and biological evaluation of N-(2-amino-phenyl)-5-(4-aryl- pyrimidin-2-yl) amino)-1H-indole-2-carboxamide derivatives as novel inhibitors of CDK9 and class I HDACs for cancer treatment. (Pubmed Central) - Jun 5, 2025
The cellular assays revealed that 13ea induced mitochondria-related apoptosis and G2/M phase arrest in cancer cells, showing superior activities compared to those of AZD-5438 (a CDK9 inhibitor) and Mocetinostat (an inhibitor of class I HDACs). Notably, the in vivo assay demonstrated that 13ea (30
- | Journal: Age-linked DNA methylation and gene expression patterns in parameningeal head and neck alveolar rhabdomyosarcoma reveal CDK9 as a promising therapeutic target. (Pubmed Central) - Jun 4, 2025
Despite the small sample size, these findings suggest potential age-related molecular mechanisms and highlight candidate genes for further investigation as novel therapeutic targets. Notably, we identified CDK9 as a promising target, warranting further exploration in the context of ARMS treatment.
- | Journal: Dynamic transcription pre-initiation complex assembly governs initiation efficiency. (Pubmed Central) - Jun 4, 2025
In contrast, non-canonical assembly, where Pol II binds first followed by TFIID, supports more efficient initiation with lower pausing. Together, these findings establish that transcription initiation efficiency is shaped by both the kinetic stability of Pol II engagement and the temporal order of pre-initiation complex assembly, providing a new framework for understanding dynamic gene regulation in vivo.
- | Journal: Analysis, isolation and anti-tumour activity of the alkaloids from Ceratocarpus arenarius L. (Pubmed Central) - Jun 3, 2025
Together, these findings establish that transcription initiation efficiency is shaped by both the kinetic stability of Pol II engagement and the temporal order of pre-initiation complex assembly, providing a new framework for understanding dynamic gene regulation in vivo. The cytotoxicity of the isolated compounds was investigated using KYSE70 cells in vitro and the results indicated that compounds (1) and (5) showed the best inhibitory effects against the KYSE70 with IC50 of 24.26?
- | SNS-032 / Viracta Therap
Journal: Design and synthesis of CDK9/EZH2 dual-target inhibitors to achieve synergistic antitumor effects. (Pubmed Central) - May 29, 2025
Notably, compound D16 induced more significant DNA damage and exhibited greater inhibition of DLBCL proliferation than the single-target inhibitor SNS-032 or C24. In addition, D16 showed potent anti-proliferative activities in various solid tumor cell lines, which may provide an innovative strategy for the treatment of cancer.
- | zemirciclib (AZD4573) / AstraZeneca
Journal: Differential activity of specific inhibitors of transcription regulating cyclin-dependent kinases in thyroid cancer cells. (Pubmed Central) - May 29, 2025
We selected thyroid cancer cell lines with a variety of genetic drivers for initial screening studies with CDK7/12/13 (THZ1) and CDK9 (AZD4573) inhibitors...Combined reduction in CDK12/13 levels with siRNA reduced RNAPII phosphorylation. These data suggest that specific inhibitors of CDK12/13 may be particularly active in thyroid cancer cell lines; further studies evaluating their efficacy are warranted in thyroid cancer.
- | Journal: Design, synthesis, biological evaluation and in silico studies of 2-anilino- 4-(benzimidazol- 1-yl)pyrimidine scaffold as antitumor agents. (Pubmed Central) - May 23, 2025
In silico ADMET results showed that all compounds have favourable drug-like properties since they met Lipinski's rule of five criteria. Overall, the synthesized anilinopyrimidine derivatives exhibit significant potential as chemotherapeutic agents.
- | Journal: HIV-1 Nef activates proviral DNA transcription by recruiting Src kinase to phosphorylate host protein Nef-associated factor 1 to compromise its viral restrictive function. (Pubmed Central) - May 20, 2025
Nef recruits Src kinase to phosphorylate Naf1, and the phosphorylation of Naf1 converts its normal restrictive role to coordinate with Nef to activate proviral DNA transcription by stimulating the downstream PI3K/AKT/mTOCR1/CDK9 cellular pathway. These findings also report a new interaction mode between host factors and viral proteins in regulating HIV-1 replication.
- DISCOVERY OF FIRST-IN-CLASS PRECISION ANTIBODY DRUG CONJUGATES TARGETING MUTANT CALRETICULIN FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS. (Auditorium) - May 15, 2025 - Abstract #EHA2025EHA_3475;
These findings also report a new interaction mode between host factors and viral proteins in regulating HIV-1 replication. In summary, we describe first-in-class pADCs targeting mutant CALR which selectively kill diseased MPN cells, demonstrating their potential as disease-modifying therapies for MPN.
- Venclexta (venetoclax) / Roche, AbbVie, sunaciclib (AU-07) - Qianhong Bio / Pharma, Aucentra
HIGH REMISSION RATES IN RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA WITH QHRD107 (CDK9 INHIBITOR), VENETOCLAX, AND AZACITIDINE COMBINATION THERAPY (107VA REGIMEN): PRELIMINARY RESULTS FROM A PHASE 2A STUDY (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_2673;
In summary, we describe first-in-class pADCs targeting mutant CALR which selectively kill diseased MPN cells, demonstrating their potential as disease-modifying therapies for MPN. The 107VA regimen demonstrated preliminarily activity and was well tolerated at tested doses, showing a high cCR rate, particularly in pateints relapsed from VEN-AZA therapy.
- bleximenib (JNJ-6617) / J&J
HIGH THROUGHPUT DRUG SCREEN COUPLED TO PROTEO-GENOMIC DATA IDENTIFIES EPIGENETIC VULNERABILITIES IN AML SUBTYPE-SPECIFIC PATIENT GROUP (Poster Hall) - May 15, 2025 - Abstract #EHA2025EHA_2589;
In conclusion, with this epigenetic drug screen we were able to identify promising epigenetic vulnerabilities for two major subgroups. Patient samples in subgroup one harbor FLT3, NPM1c and DNMT3A mutations and subgroup two is consisting of RUNX1-mutated patients and patients with splicing genes mutations.1Hogeling SM, L